Fusion Pharmaceuticals Inc. Stock Price, News & Analysis

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced on March 24, 2022, that its Board of Directors granted stock options to purchase 25,800 shares of common stock to two new employees. The options have an exercise price of $7.50 per share, matching the closing stock price on March 21, 2022. These options vest over four years, beginning with 25% on the first anniversary. Fusion focuses on developing next-generation radiopharmaceuticals, with ongoing Phase 1 trials for its lead program, FPI-1434, and collaborations with AstraZeneca and Merck for targeted therapies.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) reported financial results for Q4 2021, showing a net loss of $17.2 million, or $0.40 per share, an increase from the previous year's loss of $13.4 million. As of December 31, 2021, the company had $220.8 million in cash and investments, sufficient to fund operations through 2023.

The company advances its first targeted alpha therapy candidate in collaboration with AstraZeneca and is expanding its pipeline into peptide-based radiopharmaceuticals. Phase 1 data for candidate FPI-1434 is expected in the second half of 2022.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced on March 9, 2022, that its Board of Directors granted stock option awards for 101,200 shares of common stock to two new employees, outside of the 2020 Stock Option and Incentive Plan. The exercise price is set at $7.00 per share, equal to the March 7 closing price. Each option has a ten-year term and vests over four years. Fusion specializes in developing radiopharmaceuticals for oncology, with ongoing clinical trials for its lead product, FPI-1434, among others, and collaborations with AstraZeneca and Merck.

Fusion Pharmaceuticals (Nasdaq: FUSN) announced its participation in the "Novel Oncology Targets" panel at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 12:50 p.m. ET. CEO John Valliant, Ph.D. will represent the company. A webcast of the event will be available on their website, with a replay accessible for about 30 days. Fusion is focused on developing next-generation radiopharmaceuticals as precision medicines, with ongoing clinical trials and collaborations with major partners like AstraZeneca and Merck.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) has granted stock options to purchase 12,600 shares of common stock to a new employee, as per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.07, matching the company's closing stock price on February 7, 2022. These options feature a ten-year term and vest over four years. Fusion focuses on next-generation radiopharmaceuticals, with a pipeline including FPI-1434 in Phase 1 trials and collaborations with AstraZeneca and Merck for targeted therapies.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced its participation in the B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022, at 2:00 p.m. ET. CEO John Valliant, Ph.D., will present on behalf of the company. A webcast of the event will be available on the company's website, with a replay accessible for 90 days post-presentation. Fusion focuses on developing precision medicines through next-generation radiopharmaceuticals, with its lead program, FPI-1434, currently in Phase 1 clinical trials, and collaborations with AstraZeneca and Merck.

Fusion Pharmaceuticals Inc. granted stock option awards for 119,000 shares to a new employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.60 per share, equal to the closing price on January 14, 2022. Each option has a ten-year term and vesting schedule, with 25% vesting after one year and the remaining vesting monthly over three years. Fusion focuses on developing radiopharmaceuticals as precision medicines, with its lead program in Phase 1 clinical trials.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company, announced a strategic research collaboration with Pepscan Therapeutics B.V. to discover novel peptide-based radiopharmaceuticals targeting solid tumors. This collaboration grants Fusion global rights to develop and commercialize any peptides discovered. Fusion aims to leverage its internal capabilities and Pepscan's proprietary platform for peptide discovery, enhancing its pipeline of targeted alpha therapies (TATs). Notably, Fusion's lead program, FPI-1434, is currently in Phase 1 clinical trials targeting the insulin-like growth factor 1 receptor.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) has entered a strategic research collaboration with 48 Hour Discovery Inc. to develop novel peptide-based radiopharmaceuticals targeting various solid tumors. This partnership grants Fusion global rights to commercialize any resulting peptides. CEO John Valliant emphasized that this collaboration enhances their capabilities in targeted alpha therapies (TATs), leveraging their existing drug programs and internal research capabilities. Fusion's lead program, FPI-1434, is in Phase 1 trials, underscoring their commitment to advancing oncology treatments.